AVENIO ctDNA Surveillance Kit V2
For Research Use Only. Not for use in diagnostic procedures.
Overview
The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy research assay that’s specially designed and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer (CRC) research. The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1
Features and Benefits
- Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
- Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
- Includes reagents, bioinformatics and software
- Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days
Exceptional Performance3
A portfolio of NGS liquid biopsy assays
The AVENIO ctDNA Surveillance Kit V2 is one of three assays in the AVENIO ctDNA research assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit V2 for guideline-driven tumor profiling or the 77-gene AVENIO ctDNA Expanded Kit V2 for profiling emerging and guideline-driven biomarkers.
References
- National Comprehensive Cancer Network. Accessed August 2, 2023.
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
- Data on file with Roche.